<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">20038726</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>02</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1527-7755</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>28</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2010</Year>
<Month>Feb</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
<ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>620-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2009.23.8485</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To describe chemotherapy use and adverse events (AEs) for advanced-stage, non-small-cell lung cancer (NSCLC) in community practice, including descriptions according to variation by age.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We interviewed patients with newly diagnosed, stages IIIB and IV NSCLC in the population-based cohort studied by the Cancer Care Outcomes Research and Surveillance Consortium, and we abstracted the patient medical records. AEs were medical events occurring during chemotherapy. Using logistic regression, we assessed the association between age and chemotherapy; with Poisson regression, we estimated event rate ratios and adjusted the analysis for age, sex, ethnicity, radiation therapy, stage, histology, and presence and grade of 27 comorbidities.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 1,371 patients, 58% (95% CI, 55% to 61%) received chemotherapy and 35% (95% CI, 32% to 38%) had AEs. After adjustment, 72% (95% CI, 65% to 79%) of those younger than 55 years and 47% (95% CI, 42% to 52%) of those age 75 years and older received chemotherapy. Platinum-based therapies were less common in the older-age groups. Pretreatment medical event rates were 18.6% for patients younger than 55 years and were only 9.2% for those age 75 years and older (adjusted rate ratio, 0.49; 95% CI, 0.26 to 0.91). In contrast, older adults were more likely to have AEs during chemotherapy. The adjusted rate ratios compared with age younger than 55 years were 1.70 for 65- to 74-year-olds (95% CI, 1.19 to 2.43) and 1.34 for those age 75 years and older (95% CI, 0.90 to 2.00).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Older patients who received chemotherapy had fewer pretherapy events than younger patients and were less likely to receive platinum-based regimens. Nevertheless, older patients had more adverse events during chemotherapy, independent of comorbidity. Potential implicit trade-offs between symptom management and treatment toxicity should be made explicit and additionally studied.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chrischilles</LastName>
<ForeName>Elizabeth A</ForeName>
<Initials>EA</Initials>
<AffiliationInfo>
<Affiliation>Department of Epidemiology, University of Iowa, Iowa City, IA 52242, USA. e-chrischilles@uiowa.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pendergast</LastName>
<ForeName>Jane F</ForeName>
<Initials>JF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kahn</LastName>
<ForeName>Katherine L</ForeName>
<Initials>KL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wallace</LastName>
<ForeName>Robert B</ForeName>
<Initials>RB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moga</LastName>
<ForeName>Daniela C</ForeName>
<Initials>DC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harrington</LastName>
<ForeName>David P</ForeName>
<Initials>DP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kiefe</LastName>
<ForeName>Catarina I</ForeName>
<Initials>CI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weeks</LastName>
<ForeName>Jane C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>West</LastName>
<ForeName>Dee W</ForeName>
<Initials>DW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zafar</LastName>
<ForeName>S Yousuf</ForeName>
<Initials>SY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fletcher</LastName>
<ForeName>Robert H</ForeName>
<Initials>RH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>5 U18 HS016094</GrantID>
<Acronym>HS</Acronym>
<Agency>AHRQ HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 A093326</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA093329</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA093348</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA093324</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U18 HS016094</GrantID>
<Acronym>HS</Acronym>
<Agency>AHRQ HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA093344</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA093332</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA01013</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2009</Year>
<Month>12</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Clin Oncol</MedlineTA>
<NlmUniqueID>8309333</NlmUniqueID>
<ISSNLinking>0732-183X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>J Clin Oncol. 2010 May 1;28(13):2314</RefSource>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Clin Oncol. 2010 Feb 1;28(4):523-6</RefSource>
<PMID Version="1">20038720</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000556">secondary</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2009</Year>
<Month>12</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2009</Year>
<Month>12</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>2</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20038726</ArticleId>
<ArticleId IdType="pii">JCO.2009.23.8485</ArticleId>
<ArticleId IdType="doi">10.1200/JCO.2009.23.8485</ArticleId>
<ArticleId IdType="pmc">PMC2815997</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>N Engl J Med. 1999 Dec 30;341(27):2061-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10615079</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chest. 2000 May;117(5):1239-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10807806</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Health Qual Life Outcomes. 2008;6:84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18939982</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2001 Feb 15;19(4):1064-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11181670</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncologist. 2001;6 Suppl 1:4-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11181997</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biometrics. 1999 Jun;55(2):652-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11318229</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2001 Sep;33 Suppl 1:S115-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11576716</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2002 Jan 10;346(2):92-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11784875</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2003 Aug 15;98(4):779-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12910523</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 Aug 1;22(15):2992-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15284250</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 Aug 15;22(16):3261-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15310770</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 2004 Oct;46(1):61-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15364134</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 1995 Oct 7;311(7010):899-909</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7580546</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 1995 Dec;13(3):235-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8719064</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 1997 Mar;33(3):392-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9155522</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1998 Apr;16(4):1582-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9552069</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1998 Nov 1;83(9):1930-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9806651</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lung Cancer. 1998 Aug;21(2):105-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9829544</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 Dec 15;22(24):4971-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15611512</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chest. 2005 Aug;128(2):947-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16100191</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Intern Med J. 2006 Apr;36(4):216-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16640737</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Support Care Cancer. 2006 Aug;14(8):837-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16482448</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2007 Dec 10;25(35):5570-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18065729</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>